Lung-MAP precision medicine trial expands to include more patients

(SWOG) The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), part of the National Institutes of Health, is undergoing a major expansion to include patients with all non-small cell lung cancers -- which make up about 85 percent of all lung cancer diagnoses in the US.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news